Inclusion Criteria:

- Patients must be >= 18 years of age

- Patients must be newly diagnosed with primary invasive ductal breast adenocarcinoma.

- Tumor classified as clinically stage T2, T3 or T4 with any N (NX, N1, N2, or N3).

- Tumor does not express the following biomarkers: estrogen receptor, progesterone
receptor, Her2/neu

- Adequate organ function defined as:

- Serum Creatinine <= 1.5 x upper limit of institutional normal.

- ALT, AST, ALK Phos <= 1.5 x upper limit of institutional normal.

- Bilirubin <= 1.5 x upper limit of institutional normal.

- Normal left ventricular function (LVEF > 50%) by MUGA or ECHO.

Exclusion Criteria:

- No evidence of distant metastasis present by CT, Bone scan, or physical exam. If the
bone scan or CT scans demonstrate indeterminate lesions, the nature of these lesions
should be further clarified by additional testing such as PET or MRI.

- No prior malignancies with the exception of curatively treated basal or squamous
carcinoma of the skin or history of previous malignancies, treated with at least
greater than 5 years disease free survival.

- Women of child bearing potential may not be currently pregnant or breastfeeding at
time of registration and must agree to use adequate contraception.

- Karnofsky Performance Status of <= 70.

- Patients with known history neural deficiencies (e.g. peripheral neuropathy).

- Patients with a known hearing impairment (hearing loss or severe tinnitus).

- Male patients